Eli Lilly Operating Margin 1986-2025 | LLY

Current and historical operating margin for Eli Lilly (LLY) over the last 10 years. The current operating profit margin for Eli Lilly as of June 30, 2025 is 23.89%.
Eli Lilly Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2025-06-30 $53.26B $16.80B 31.55%
2025-03-31 $49.00B $14.09B 28.74%
2024-12-31 $45.04B $12.90B 28.64%
2024-09-30 $40.86B $10.43B 25.51%
2024-06-30 $38.92B $9.50B 24.40%
2024-03-31 $35.93B $7.47B 20.80%
2023-12-31 $34.12B $6.46B 18.93%
2023-09-30 $32.07B $8.88B 27.69%
2023-06-30 $29.52B $7.13B 24.17%
2023-03-31 $27.69B $6.22B 22.45%
2022-12-31 $28.54B $7.13B 24.97%
2022-09-30 $29.24B $7.21B 24.65%
2022-06-30 $29.07B $7.41B 25.50%
2022-03-31 $29.32B $7.61B 25.94%
2021-12-31 $28.32B $6.36B 22.44%
2021-09-30 $27.76B $6.43B 23.17%
2021-06-30 $26.73B $5.83B 21.81%
2021-03-31 $25.49B $5.62B 22.06%
2020-12-31 $24.54B $6.06B 24.69%
2020-09-30 $23.21B $5.47B 23.55%
2020-06-30 $22.95B $5.62B 24.48%
2020-03-31 $23.09B $5.92B 25.64%
2019-12-31 $22.32B $4.97B 22.28%
2019-09-30 $21.84B $4.47B 20.48%
2019-06-30 $21.67B $4.39B 20.24%
2019-03-31 $21.62B $2.88B 13.33%
2018-12-31 $21.49B $3.53B 16.44%
2018-09-30 $19.12B $2.91B 15.24%
2018-06-30 $19.47B $2.11B 10.85%
2018-03-31 $19.71B $3.32B 16.83%
2017-12-31 $19.97B $2.00B 10.03%
2017-09-30 $22.47B $2.40B 10.70%
2017-06-30 $22.01B $2.81B 12.75%
2017-03-31 $21.59B $2.53B 11.72%
2016-12-31 $21.22B $3.26B 15.37%
2016-09-30 $20.84B $2.91B 13.97%
2016-06-30 $20.61B $2.93B 14.21%
2016-03-31 $20.18B $2.88B 14.27%
2015-12-31 $19.96B $2.69B 13.47%
2015-09-30 $19.71B $2.67B 13.55%
2015-06-30 $19.62B $2.31B 11.76%
2015-03-31 $19.58B $2.32B 11.84%
2014-12-31 $19.62B $2.66B 13.56%
2014-09-30 $20.30B $3.23B 15.91%
2014-06-30 $21.20B $4.18B 19.70%
2014-03-31 $22.20B $4.79B 21.59%
2013-12-31 $23.11B $5.37B 23.24%
2013-09-30 $23.26B $5.50B 23.66%
2013-06-30 $22.93B $5.10B 22.23%
2013-03-31 $22.60B $4.80B 21.22%
2012-12-31 $22.60B $4.73B 20.94%
2012-09-30 $22.69B $4.72B 20.78%
2012-06-30 $23.40B $5.16B 22.06%
2012-03-31 $24.05B $5.55B 23.07%
2011-12-31 $24.29B $5.53B 22.76%
2011-09-30 $24.43B $5.87B 24.04%
2011-06-30 $23.93B $6.04B 25.23%
2011-03-31 $23.43B $6.23B 26.60%
2010-12-31 $23.08B $6.53B 28.30%
2010-09-30 $22.82B $5.75B 25.17%
2010-06-30 $22.73B $5.68B 24.98%
2010-03-31 $22.28B $5.49B 24.66%
2009-12-31 $21.84B $5.59B 25.59%
2009-09-30 $21.11B $1.86B 8.82%
2009-06-30 $20.75B $1.60B 7.70%
2009-03-31 $20.61B $1.27B 6.14%
2008-12-31 $20.37B $0.69B 3.40%
2008-09-30 $20.36B $4.99B 24.50%
2008-06-30 $19.74B $4.77B 24.19%
2008-03-31 $19.22B $4.44B 23.08%
2007-12-31 $18.63B $4.06B 21.77%
2007-09-30 $17.69B $4.00B 22.60%
2007-06-30 $16.97B $3.84B 22.62%
2007-03-31 $16.20B $3.91B 24.11%
2006-12-31 $15.69B $4.13B 26.30%
2006-09-30 $15.33B $4.05B 26.43%
2006-06-30 $15.06B $3.93B 26.12%
2006-03-31 $14.86B $3.83B 25.76%
2005-12-31 $14.65B $3.65B 24.92%
2005-09-30 $14.41B $3.61B 25.07%
2005-06-30 $14.09B $3.54B 25.15%
2005-03-31 $13.98B $3.56B 25.48%
2004-12-31 $13.86B $3.27B 23.58%
2004-09-30 $13.68B $3.21B 23.48%
2004-06-30 $13.54B $3.28B 24.21%
2004-03-31 $13.07B $3.23B 24.71%
2003-12-31 $12.58B $3.50B 27.83%
2003-09-30 $12.07B $3.51B 29.03%
2003-06-30 $11.72B $3.39B 28.90%
2003-03-31 $11.41B $3.32B 29.09%
2002-12-31 $11.08B $3.25B 29.29%
2002-09-30 $10.95B $3.04B 27.78%
2002-06-30 $11.04B $3.03B 27.48%
2002-03-31 $11.30B $3.29B 29.14%
2001-12-31 $11.54B $3.54B 30.67%
2001-09-30 $11.69B $3.77B 32.26%
2001-06-30 $11.63B $3.98B 34.26%
2001-03-31 $11.22B $3.76B 33.54%
2000-12-31 $10.86B $3.56B 32.77%
2000-09-30 $10.71B $3.61B 33.69%
2000-06-30 $10.48B $3.49B 33.30%
2000-03-31 $10.20B $3.40B 33.38%
1999-12-31 $10.00B $3.36B 33.63%
1999-09-30 $9.82B $3.64B 37.05%
1999-06-30 $9.81B $3.52B 35.94%
1999-03-31 $9.81B $3.43B 34.94%
1998-12-31 $9.82B $3.41B 34.69%
1998-09-30 $9.44B $2.64B 28.01%
1998-06-30 $9.03B $2.50B 27.69%
1998-03-31 $8.69B $2.41B 27.73%
1997-12-31 $8.37B $2.31B 27.62%
1997-09-30 $8.17B $2.37B 29.00%
1997-06-30 $7.82B $2.27B 29.00%
1997-03-31 $7.52B $2.16B 28.70%
1996-12-31 $7.35B $2.05B 27.87%
1996-09-30 $7.09B $1.96B 27.69%
1996-06-30 $6.91B $1.93B 27.96%
1996-03-31 $6.83B $1.95B 28.57%
1995-12-31 $6.76B $1.98B 29.32%
1995-09-30 $6.51B $1.95B 29.93%
1995-06-30 $6.39B $1.92B 30.01%
1995-03-31 $6.45B $2.22B 34.38%
1994-12-31 $6.04B $2.13B 35.20%
1994-09-30 $6.30B $2.15B 34.20%
1994-06-30 $6.32B $2.09B 33.07%
1994-03-31 $6.20B $1.79B 28.81%
1993-12-31 $6.45B $1.83B 28.28%
1993-09-30 $6.31B $1.87B 29.63%
1993-06-30 $6.25B $1.67B 26.68%
1993-03-31 $6.17B $1.65B 26.73%
1992-12-31 $6.17B $1.72B 27.91%
1992-09-30 $6.09B $1.66B 27.33%
1992-06-30 $5.95B $1.86B 31.27%
1992-03-31 $5.85B $1.85B 31.67%
1991-12-31 $5.73B $1.77B 30.88%
1991-09-30 $5.60B $1.72B 30.73%
1991-06-30 $5.54B $1.68B 30.28%
1991-03-31 $5.39B $1.61B 29.79%
1990-12-31 $5.19B $1.54B 29.64%
1990-09-30 $4.53B $1.37B 30.12%
1990-06-30 $4.30B $1.25B 29.10%
1990-03-31 $4.19B $1.19B 28.46%
1989-12-31 $4.18B $1.16B 27.87%
1989-09-30 $3.97B $1.07B 26.86%
1989-06-30 $3.87B $1.05B 27.12%
1989-03-31 $3.76B $1.00B 26.51%
1988-12-31 $3.61B $0.92B 25.53%
1988-09-30 $3.64B $0.64B 17.67%
1988-06-30 $3.66B $0.63B 17.24%
1988-03-31 $3.66B $0.61B 16.79%
1987-12-31 $3.65B $0.58B 16.02%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $495.141B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12